Targeted, Site-Specific, Delivery Vehicles of Therapeutics for COVID-19 Patients. Brief Review
Definitive pharmacological therapies for COVID-19 have yet to be identified. Several hundred trials are ongoing globally in the hope of a solution. However, nearly all treatments rely on systemic delivery but COVID-19 damages the lungs preferentially. The use of a targeted delivery approach is revie...
Main Authors: | Nicholas Kipshidze MD, PhD, DSc, Patrick Iversen PhD, Thomas R. Porter MD, Nodar Kipshidze MPH, Fakiha Siddiqui BDS, George Dangas MD, PhD, Jawed Fareed PhD |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2020-09-01
|
Series: | Clinical and Applied Thrombosis/Hemostasis |
Online Access: | https://doi.org/10.1177/1076029620954911 |
Similar Items
-
Viral Coagulopathy in Patients With COVID-19: Treatment and Care
by: Nickolas Kipshidze MD, PhD, DSc, et al.
Published: (2020-07-01) -
Catheter-Based Local Delivery of Therapeutics to the Lungs for Severe or Critically Ill Patients with COVID-19
by: George Dangas, et al.
Published: (2021-02-01) -
Is the Reason of Increased D-Dimer Levels in COVID-19 Because of ACE-2-Induced Apoptosis in Endothelium?
by: Nil Guler MD, et al.
Published: (2020-07-01) -
Factor Xa Inhibitory Profile of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban Does Not Fully Reflect Their Biologic Spectrum
by: Fakiha Siddiqui BDS, et al.
Published: (2019-05-01) -
Comparative Anticoagulant and Thrombin Generation Inhibitory Profile of Heparin, Sulodexide and Its Components
by: Fakiha Siddiqui BDS, et al.
Published: (2020-10-01)